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Background: Patients receiving prosthetic heart valves have well documented additional lifetime costs. This study models the differences in the 
lifetime cost of health care consumed by prosthesis type: (Stented Tissue (ST) or Mechanical Valve (MV)).
methods: The model estimates cost for On-X Life Technologies MV vs. ST with standard surgical aortic valve replacement at re-operation (between 
10 and 25 years) assuming 25 year survival and 3% medical inflation. Complication event rate estimates were obtained from peer reviewed journals 
by prosthesis type. Clinical events include: initial valve surgery, thrombotic events, bleeding events, warfarin and monitoring, echo monitoring, 
paravalular leak, endocarditis, pacemaker insertion following valve surgery, and re-operation due to structural valve disease.
results: The chart shows lifetime healthcare cost curves between using ST vs. MV and annual savings. Total costs are estimated to be $183,600 
for ST versus $124,200 using MV: a $59,400 (~48%) lifetime cost saving for using MV for initial implantation. The Savings Curve indicates a small 
annual savings for MV for the first decade, and increasing after year 10 due to higher costs associated with reoperation.
conclusions: This study demonstrates lifetime savings of $59,400 by implanting MV vs. ST. Using MV for the estimated 20,000 ST valve surgeries 
performed annually in the U.S. in patients below age 65 would potentially result in nearly $1.2 billion lifetime reduction in healthcare expenditures.
 
